BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

158 related articles for article (PubMed ID: 38197078)

  • 21. A Novel Lipid Prognostic Signature of ADCY2, LIPE, and OLR1 in Head and Neck Squamous Cell Carcinoma.
    Gao X; Zhao N; Dong L; Zheng X; Zhang Y; Ding C; Zhao S; Ma Z; Wang Y
    Front Oncol; 2021; 11():735993. PubMed ID: 34900686
    [TBL] [Abstract][Full Text] [Related]  

  • 22. The Proteomic Landscape of Growth Factor Signaling Networks Associated with
    Chen Z; Zhang C; Chen J; Wang D; Tu J; Van Waes C; Saba NF; Chen ZG; Chen Z
    Cancer Res; 2021 Sep; 81(17):4402-4416. PubMed ID: 34167951
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Computational analysis of TP53 mutational landscape unveils key prognostic signatures and distinct pathobiological pathways in head and neck squamous cell cancer.
    Caponio VCA; Troiano G; Adipietro I; Zhurakivska K; Arena C; Mangieri D; Mascitti M; Cirillo N; Lo Muzio L
    Br J Cancer; 2020 Oct; 123(8):1302-1314. PubMed ID: 32684626
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Comprehensive genomic profiling of head and neck squamous cell carcinoma reveals FGFR1 amplifications and tumour genomic alterations burden as prognostic biomarkers of survival.
    Dubot C; Bernard V; Sablin MP; Vacher S; Chemlali W; Schnitzler A; Pierron G; Ait Rais K; Bessoltane N; Jeannot E; Klijanienko J; Mariani O; Jouffroy T; Calugaru V; Hoffmann C; Lesnik M; Badois N; Berger F; Le Tourneau C; Kamal M; Bieche I
    Eur J Cancer; 2018 Mar; 91():47-55. PubMed ID: 29331751
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Targeted sequencing reveals TP53 as a potential diagnostic biomarker in the post-treatment surveillance of head and neck cancer.
    van Ginkel JH; de Leng WW; de Bree R; van Es RJ; Willems SM
    Oncotarget; 2016 Sep; 7(38):61575-61586. PubMed ID: 27528217
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Mutated
    Kampel L; Feldstein S; Tsuriel S; Hannes V; Carmel Neiderman NN; Horowitz G; Warshavsky A; Leider-Trejo L; Hershkovitz D; Muhanna N
    Biomolecules; 2023 Sep; 13(9):. PubMed ID: 37759818
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Integrated multi-omics analysis identifies CD73 as a prognostic biomarker and immunotherapy response predictor in head and neck squamous cell carcinoma.
    Shen A; Ye Y; Chen F; Xu Y; Zhang Z; Zhao Q; Zeng ZL
    Front Immunol; 2022; 13():969034. PubMed ID: 36466881
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Expression of TP53 mutation-associated microRNAs predicts clinical outcome in head and neck squamous cell carcinoma patients.
    Ganci F; Sacconi A; Bossel Ben-Moshe N; Manciocco V; Sperduti I; Strigari L; Covello R; Benevolo M; Pescarmona E; Domany E; Muti P; Strano S; Spriano G; Fontemaggi G; Blandino G
    Ann Oncol; 2013 Dec; 24(12):3082-8. PubMed ID: 24107801
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Significance of
    Jin Y; Qin X
    Biomark Med; 2021 Jan; 15(1):15-28. PubMed ID: 33427498
    [No Abstract]   [Full Text] [Related]  

  • 30. Identification of m6A methyltransferase-related genes predicts prognosis and immune infiltrates in head and neck squamous cell carcinoma.
    Zhang Y; Li L; Ye Z; Zhang L; Yao N; Gai L
    Ann Transl Med; 2021 Oct; 9(20):1554. PubMed ID: 34790760
    [TBL] [Abstract][Full Text] [Related]  

  • 31. The
    Moe SE; Erland FA; Fromreide S; Lybak S; Brydoy M; Dongre HN; Dhayalan SM; Costea DE; Vintermyr OK; Aarstad HJ
    Biomedicines; 2023 Jun; 11(7):. PubMed ID: 37509476
    [TBL] [Abstract][Full Text] [Related]  

  • 32. The differences of immunologic and TP53 mutant phenotypes between synchronous and metachronous head and neck cancer and esophageal cancer.
    Chen TC; Wu CT; Wang CP; Lou PJ; Ko JY; Chang YL
    Oral Oncol; 2020 Dec; 111():104945. PubMed ID: 32769036
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Association of TP53 and CDKN2A Mutation Profile with Tumor Mutation Burden in Head and Neck Cancer.
    Deneka AY; Baca Y; Serebriiskii IG; Nicolas E; Parker MI; Nguyen TT; Xiu J; Korn WM; Demeure MJ; Wise-Draper T; Sukari A; Burtness B; Golemis EA
    Clin Cancer Res; 2022 May; 28(9):1925-1937. PubMed ID: 35491653
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Immunosignatures associated with TP53 status and co-mutations classify prognostically head and neck cancer patients.
    Sacconi A; Muti P; Pulito C; Urbani G; Allegretti M; Pellini R; Mehterov N; Ben-David U; Strano S; Bossi P; Blandino G
    Mol Cancer; 2023 Nov; 22(1):192. PubMed ID: 38031025
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Identification of factors related to immunotherapy efficacy and prognosis in patients with advanced head and neck squamous cell carcinoma.
    Xu X; Li R; Zhang L; Zhu G; Ren D; Wu L; Gong X
    Diagn Pathol; 2021 Nov; 16(1):110. PubMed ID: 34823553
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Nine-gene signature and nomogram for predicting survival in patients with head and neck squamous cell carcinoma.
    Yang F; Zhou LQ; Yang HW; Wang YJ
    Front Genet; 2022; 13():927614. PubMed ID: 36092911
    [No Abstract]   [Full Text] [Related]  

  • 37. Plasma cell-free DNA methylome profiling in pre- and post-surgery oral cavity squamous cell carcinoma.
    Patel KB; Padhya TA; Huang J; Hernandez-Prera JC; Li T; Chung CH; Wang L; Wang X
    Mol Carcinog; 2023 Apr; 62(4):493-502. PubMed ID: 36636912
    [TBL] [Abstract][Full Text] [Related]  

  • 38. The amount of DNA combined with TP53 mutations in liquid biopsy is associated with clinical outcome of renal cancer patients treated with immunotherapy and VEGFR-TKIs.
    Del Re M; Crucitta S; Paolieri F; Cucchiara F; Verzoni E; Bloise F; Ciampi R; Mercinelli C; Capuano A; Sportiello L; Martinetti A; Procopio G; Galli L; Porta C; Bracarda S; Danesi R
    J Transl Med; 2022 Aug; 20(1):371. PubMed ID: 35974365
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Targeted Next-Generation Sequencing of Cancer-Related Genes in a Norwegian Patient Cohort With Head and Neck Squamous Cell Carcinoma Reveals Novel Actionable Mutations and Correlations With Pathological Parameters.
    Dongre HN; Haave H; Fromreide S; Erland FA; Moe SEE; Dhayalan SM; Riis RK; Sapkota D; Costea DE; Aarstad HJ; Vintermyr OK
    Front Oncol; 2021; 11():734134. PubMed ID: 34631566
    [TBL] [Abstract][Full Text] [Related]  

  • 40. TP53 mutations in head and neck cancer.
    Nathan CA; Khandelwal AR; Wolf GT; Rodrigo JP; Mäkitie AA; Saba NF; Forastiere AA; Bradford CR; Ferlito A
    Mol Carcinog; 2022 Apr; 61(4):385-391. PubMed ID: 35218075
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 8.